Advances in the Treatment of Hepatitis C Virus Infection from The Liver Meeting 2013

The 64th Annual Meeting of the American Association for the Study of Liver Diseases

November 1-5, 2013 • Washington DC

Special Reporting on:

• Simeprevir plus Sofosbuvir with or without Ribavirin Produces High SVR Rates in Genotype 1 HCV Infection
• Novel Interferon- and Ribavirin-Free Regimen Results in SVR12 Rates of Over 90% in HCV Genotype 1b Infection
• Studies Confirm Efficacy of Adjunctive Simeprevir in Difficult-to-Treat HCV Genotype 1 Subpopulations
• All-Oral Therapy with Sofosbuvir Plus Ribavirin Produces High SVR Rates in Patients Coinfected with HCV and HIV
• Faldaprevir Combined with Pegylated Interferon and Ribavirin Demonstrates High Efficacy in Difficult-to-Treat HCV Infection
• Once Daily Sofosbuvir/Ledipasvir Combination Elicits Rapid Decline in HCV RNA

  PLUS Meeting Abstract Summaries

  With Expert Commentary by:

  Ira M. Jacobson, MD

  Weill Cornell Medical College New York, New York